JurisdictionsTopicsUpdatesWorkflowsCompareChat with ExpertMarketplacePricing
🇧🇷
Medical — LegalSouth America

Brazil

Brazil authorized medical cannabis imports via ANVISA in 2015 and approved domestic cannabis-based products in 2019. Patient access has expanded significantly, with over 400,000 authorizations granted by 2025, though domestic cultivation remains restricted to pharmaceutical companies.

Ask the Expert about Brazil
Regulator
ANVISA
Key Legislation
RDC 327/2019
Year Legalized
2015 (imports); 2019 (domestic products)
Program Size
Over 400,000 patient authorizations a...

Key Facts

  • ANVISA grants individual import authorizations for patients with medical prescriptions
  • RDC 327/2019 created a framework for domestically manufactured cannabis products
  • Only pharmaceutical companies can cultivate — personal cultivation is generally prohibited
  • The Supreme Court has heard cases on decriminalization, creating ongoing legal uncertainty
  • Products must contain primarily CBD; THC-dominant products face stricter controls

Key Legislation

RDC 327/2019 (ANVISA Resolution)

Regulatory Body

ANVISA (National Health Surveillance Agency)

Country Info
ISO Code
BR
Region
South America
Tier
Tier 1 — Active Program
Status
Medical — Legal
Sources
ANVISA — Cannabis MedicinalRDC 327/2019 Text
Disclaimer: This information is for general reference only and does not constitute legal advice. Cannabis regulations change frequently. Always verify with official sources and local legal counsel before making compliance decisions.